Literature DB >> 30138630

Paradoxical LTP maintenance with inhibition of protein synthesis and the proteasome suggests a novel protein synthesis requirement for early LTP reversal.

Paul Smolen1, Douglas A Baxter2, John H Byrne2.   

Abstract

The transition from early long-term potentiation (E-LTP) to late long-term potentiation (L-LTP) is a multistep process that involves both protein synthesis and degradation. The ways in which these two opposing processes interact to establish L-LTP are not well understood, however. For example, L-LTP is attenuated by inhibiting either protein synthesis or proteasome-dependent degradation prior to and during a tetanic stimulus (e.g., Huang et al., 1996; Karpova et al., 2006), but paradoxically, L-LTP is not attenuated when synthesis and degradation are inhibited simultaneously (Fonseca et al., 2006). These paradoxical results suggest that counter-acting 'positive' and 'negative' proteins regulate L-LTP. To investigate the basis of this paradox, we developed a model of LTP at the Schaffer collateral to CA1 pyramidal cell synapse. The model consists of nine ordinary differential equations that describe the levels of both positive- and negative-regulator proteins (PP and NP, respectively) and the transitions among five discrete synaptic states, including a basal state (BAS), three states corresponding to E-LTP (EP1, EP2, and ED), and a L-LTP state (LP). An LTP-inducing stimulus: 1) initiates the transition from BAS to EP1 and from EP1 to EP2; 2) initiates the synthesis of PP and NP; and finally; 3) activates the ubiquitin-proteasome system (UPS), which in turn, mediates transitions of EP1 and EP2 to ED and the degradation of NP. The conversion of E-LTP to L-LTP is mediated by the PP-dependent transition from ED to LP, whereas NP mediates reversal of EP2 to BAS. We found that the inclusion of the five discrete synaptic states was necessary to simulate key empirical observations: 1) normal L-LTP, 2) block of L-LTP by either proteasome inhibitor or protein synthesis inhibitor alone, and 3) preservation of L-LTP when both inhibitors are applied together. Although our model is abstract, elements of the model can be correlated with specific molecular processes. Moreover, the model correctly captures the dynamics of protein synthesis- and degradation-dependent phases of LTP, and it makes testable predictions, such as a unique synaptic state (ED) that precedes the transition from E-LTP to L-LTP, and a well-defined time window for the action of the UPS (i.e., during the transitions from EP1 and EP2 to ED). Tests of these predictions will provide new insights into the processes and dynamics of long-term synaptic plasticity.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Computational; Long-term potentiation; Proteasome; Simulation

Mesh:

Substances:

Year:  2018        PMID: 30138630      PMCID: PMC6179370          DOI: 10.1016/j.jtbi.2018.08.026

Source DB:  PubMed          Journal:  J Theor Biol        ISSN: 0022-5193            Impact factor:   2.691


  46 in total

1.  The ubiquitin-proteasome cascade is required for mammalian long-term memory formation.

Authors:  M Lopez-Salon; M Alonso; M R Vianna; H Viola; T Mello e Souza; I Izquierdo; J M Pasquini; J H Medina
Journal:  Eur J Neurosci       Date:  2001-12       Impact factor: 3.386

2.  Temporally graded requirement for protein synthesis following memory reactivation.

Authors:  Maria H Milekic; Cristina M Alberini
Journal:  Neuron       Date:  2002-10-24       Impact factor: 17.173

3.  Sequential Elution Interactome Analysis of the Mind Bomb 1 Ubiquitin Ligase Reveals a Novel Role in Dendritic Spine Outgrowth.

Authors:  Joseph Mertz; Haiyan Tan; Vishwajeeth Pagala; Bing Bai; Ping-Chung Chen; Yuxin Li; Ji-Hoon Cho; Timothy Shaw; Xusheng Wang; Junmin Peng
Journal:  Mol Cell Proteomics       Date:  2015-04-30       Impact factor: 5.911

4.  Structural and molecular remodeling of dendritic spine substructures during long-term potentiation.

Authors:  Miquel Bosch; Jorge Castro; Takeo Saneyoshi; Hitomi Matsuno; Mriganka Sur; Yasunori Hayashi
Journal:  Neuron       Date:  2014-04-16       Impact factor: 17.173

5.  Kalirin-7 controls activity-dependent structural and functional plasticity of dendritic spines.

Authors:  Zhong Xie; Deepak P Srivastava; Huzefa Photowala; Li Kai; Michael E Cahill; Kevin M Woolfrey; Cassandra Y Shum; D James Surmeier; Peter Penzes
Journal:  Neuron       Date:  2007-11-21       Impact factor: 17.173

6.  Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin.

Authors:  G Fenteany; R F Standaert; W S Lane; S Choi; E J Corey; S L Schreiber
Journal:  Science       Date:  1995-05-05       Impact factor: 47.728

7.  Requirement of a critical period of transcription for induction of a late phase of LTP.

Authors:  P V Nguyen; T Abel; E R Kandel
Journal:  Science       Date:  1994-08-19       Impact factor: 47.728

8.  Arc/Arg3.1 is essential for the consolidation of synaptic plasticity and memories.

Authors:  Niels Plath; Ora Ohana; Björn Dammermann; Mick L Errington; Dietmar Schmitz; Christina Gross; Xiaosong Mao; Arne Engelsberg; Claudia Mahlke; Hans Welzl; Ursula Kobalz; Anastasia Stawrakakis; Esperanza Fernandez; Robert Waltereit; Anika Bick-Sander; Eric Therstappen; Sam F Cooke; Veronique Blanquet; Wolfgang Wurst; Benedikt Salmen; Michael R Bösl; Hans-Peter Lipp; Seth G N Grant; Tim V P Bliss; David P Wolfer; Dietmar Kuhl
Journal:  Neuron       Date:  2006-11-09       Impact factor: 17.173

9.  Protein degradation by ubiquitin-proteasome system in formation and labilization of contextual conditioning memory.

Authors:  María Sol Fustiñana; Verónica de la Fuente; Noel Federman; Ramiro Freudenthal; Arturo Romano
Journal:  Learn Mem       Date:  2014-08-18       Impact factor: 2.460

10.  Role of proteasome-dependent protein degradation in long-term operant memory in Aplysia.

Authors:  Lisa C Lyons; Jacob S Gardner; Catherine E Gandour; Harini C Krishnan
Journal:  Learn Mem       Date:  2016-12-15       Impact factor: 2.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.